Valuation check: AVEFF's profit margin is -343.94%, below the Healthcare sector average of 17.63%.
Get informed when a big investor buys or sells
+ FollowAs of Jun 2026
Trailing 12 months ending Jun 2026
The latest profit margin for AVEFF is -343.94% as of June 2026. That compares with -620.53% in the prior-year period — up 44.6% year over year. That is below the Healthcare sector average of 17.63%. Investors often review this figure alongside Avecho Biotechnology Limited's historical trend and sector peers before judging valuation or financial health.
Over the past year, AVEFF's profit margin moved from -620.53% to -343.94% — a 44.6% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Avecho Biotechnology Limited's valuation or profitability profile.
Against Healthcare companies, AVEFF currently prints -343.94% for profit margin, while the sector average sits near 17.63%. That is roughly 2051.0% below the sector mean. Large gaps often invite a closer look at Avecho Biotechnology Limited's growth, margins, and balance sheet.
Profit Margin shows how effectively Avecho Biotechnology Limited converts resources into returns. At -343.94%, AVEFF may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -620.53% in the prior-year period — up 44.6% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.
After noting AVEFF's profit margin (-343.94%), review year-over-year change from -620.53%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.